A randomized phase 3 trial evaluating xevinapant with chemoradiotherapy for head and neck cancers has been discontinued due to lack of benefit. Chemoradiotherapy has been a standard treatment for this cancer type, but new approaches, including immunotherapy, have not been successful. The addition of xevinapant did not improve event-free survival for patients with advanced squamous cell carcinoma of the head and neck. The manufacturer, Merck KGaA, will continue to review the data and share findings in a peer-reviewed forum. They also stopped another trial comparing radiotherapy plus xevinapant or placebo for patients with locally advanced head and neck cancer.
Source link
Phase 3 trial of combination for advanced head, neck cancer halted due to lack of benefit
